Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national blog main
boston blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
crispr
national
boulder/denver blog main
boulder/denver top stories
crispr therapeutics
deals
detroit blog main
detroit top stories
editas medicine
gene editing
glaxosmithkline
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
clinical trials
crispr-cas9
fda
gene therapy
indiana blog main
indiana top stories
messenger rna
What
crispr
8
×
bio
roundup
cas
ceo
editas
gene
medicine
therapeutics
big
editing
katrine
million
scientists
therapy
today
access
acquisitions
advanced
albert
allergan
alliance
allogene
available
based
beam
biggest
biosciences
blessing
bosley
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
cancer
capacity
Language
unset
unknown
Current search:
biotech
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M